Aptahem Secures Chinese Patent Protection for RNA-Based Anti-Inflammatory Therapy Through 2038
核心洞察
Aptahem AB received Notice of Allowance in China for patent application covering nucleic acid molecules (搜索) with anti-inflammatory, anti-coagulant, and organ-protective properties.
The granted patent will provide intellectual property protection until 2038 for the company's RNA-based pharmaceutical technology platform.
CEO Mikael Lindstam emphasized that Chinese patent protection strengthens Aptahem's global position and attractiveness to potential partners in one of the world's largest pharmaceutical markets.
Clinical-stage biotechnology company Aptahem AB announced it has received a Notice of Allowance from Chinese patent authorities for patent application no. 2018800643106, covering nucleic acid molecules (搜索) with anti-inflammatory, anti-coagulant, and organ-protective properties. The patent, once issued, will remain valid through 2038.
Strategic Market Access in China
The Notice of Allowance represents formal communication from the Chinese patent authority indicating the application has reached allowable status for patent issuance. CEO Mikael Lindstam highlighted the strategic importance of securing intellectual property protection in China, describing it as "one of the world's largest and fastest growing markets for pharmaceutical development and biotechnology."
"Patent protection here strengthens both our global position and our attractiveness to potential partners," Lindstam stated. "This means a clear increase in value for our development portfolio and is an important step in creating long-term business value."
RNA-Based Therapeutic Platform
Aptahem develops RNA-based pharmaceuticals targeting acute, life-threatening conditions characterized by combined coagulation, inflammation, and tissue damage. The company's approach addresses multiple pathological mechanisms simultaneously through its nucleic acid molecule technology.
The lead candidate Apta-1 is currently advancing through early clinical phase development. In preclinical studies, Apta-1 demonstrated anti-thrombotic, immunomodulating, and tissue repairing characteristics, showing promising results for treating sepsis (搜索) and critical conditions associated with sepsis.
Clinical Development Focus
Aptahem's therapeutic focus centers on acute medical conditions where coagulation disorders, inflammatory responses, and tissue damage converge. This multi-target approach represents a differentiated strategy in treating complex pathophysiological states like sepsis (搜索), where traditional single-mechanism therapies have shown limited success.
The Chinese patent protection adds significant value to Aptahem's intellectual property portfolio, particularly given China's expanding role in global pharmaceutical development and biotechnology innovation.